Maastricht University

Running trials

• Not yet recruiting

  A Phase 2, open-label trial to investigate the long-term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3

  2026-526408-60-00· Phase 2· Vico Therapeutics B.V.· Source

• Recruiting

  A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

  NCT07625215· Phase 2· Bayer· Source

• Not yet recruiting

  TMSxDCS: Medicinal improvement of brain stimulation for depression.

  2025-521166-95-00· Phase 2· Universiteit Maastricht· Source

• Recruiting

  A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo

  NCT07757087· Phase 1· Novo Nordisk A/S· Source

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· The POLG Foundation· Source

• Recruiting

  Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation

  NCT07556887· Maastricht University Medical Center· Source

• Recruiting

  Effect of Probiotics on Appetite Regulation in Adults With Overweight/Obesity

  NCT07715955· Maastricht University Medical Center· Source

• Not yet recruiting

  A Study on Remote Health Support for Patients With Heart Failure.

  NCT07440472· Universitat Internacional de Catalunya· Source

• Not yet recruiting

  High-Dairy Food Patterns and Gut-Brain Axis

  NCT07355309· Maastricht University Medical Center· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  The Effects of a 4-week Supplementation With a Ketogenic Nutrient Mix on 24-hour Substrate Metabolism and Muscle Health

  NCT07395973· Maastricht University Medical Center· Source

• Recruiting

  Long-Term Effects of Walnut Consumption on Brain Function

  NCT07422220· Maastricht University Medical Center· Source

• Recruiting

  Role of BCAA in glucose homeostasis

  2023-503424-12-00· Phase 4· Maastricht University· Source

• Recruiting

  FMRI-neurofeedback in Parkinson's Disease

  NCT06582355· Maastricht University Medical Center· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  NCT06617325· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  A long-term follow-up study for patients treated with Galapagos CAR T cell therapies

  2023-510173-34-00· Phase 3· Lakefront Biotherapeutics· Source

• Recruiting

  Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure

  NCT07016477· Semmelweis University· Source

• Recruiting

  The Impact of Psilocybin on Pain in Fibromyalgia Patients

  NCT06368492· Phase 2· Maastricht University· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

  NCT06185764· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study

  2023-506698-36-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  NCT05803941· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma

  2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source

• Recruiting

  A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

  NCT05822908· Phase 1/2· Vico Therapeutics B. V.· Source

• Recruiting

  FMRI-neurofeedback in Depression

  NCT05640089· Maastricht University Medical Center· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  LEGACY

  NCT05125276· Phase 4· Amsterdam UMC· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Enrolling by invitation

  A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

  NCT04976322· Phase 3· UCB Biopharma SRL· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Cytokinetics· Source

• Active, not recruiting

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension

  NCT01471834· CVRx, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity5 recruiting
• Depression2 recruiting
• Huntington's disease2 recruiting
• Lupus (SLE)2 recruiting
• Prostate cancer2 recruiting
• Stroke2 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Epilepsy1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mitochondrial disease1 recruiting
• Multiple myeloma1 recruiting
• Myotonic dystrophy1 recruiting
• Parkinson disease1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Butyrate-enriched Triglyceride and Diabetes Prevention

  NCT06384313· Maastricht University Medical Center· Source

• Completed

  Determination of the Optimal Nutrient Mix to Acutely Increase Plasma Ketones

  NCT06511206· Maastricht University Medical Center· Source

• Withdrawn

  JDQ443 for KRAS G12C NSCLC Brain Metastases

  NCT05999357· Phase 2· Maastricht University Medical Center· Source

• Completed

  Brain Self-regulation for Parkinson's

  NCT05627895· Maastricht University· Source

• Completed

  Timing Exercise Training as Strategy to Improve Insulin Sensitivity and Substrate Metabolism in Men and Woman With Pre-diabetes

  NCT06014684· Maastricht University Medical Center· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Acute Effects of Cold-induced Shivering on 24-hour the Glucose Profile in Metabolically Compromised Populations

  NCT05576025· Maastricht University Medical Center· Source

• Completed

  The Next Step in Smoking Prevention: the Reduction of Tobacco Retail Outlets, a Comprehensive Policy Evaluation

  NCT05554120· Maastricht University Medical Center· Source

• Completed

  Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)

  NCT05354245· Maastricht University Medical Center· Source

• Completed

  Obese Human Beta-2-adrenergic Stimulation and Muscle Glucose Uptake

  NCT04921306· Phase 2· Maastricht University· Source

• Completed

  Acute Timed Exercise and 24h Metabolism

  NCT05073068· Maastricht University· Source

• Completed

  Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

  NCT05200936· Phase 2· Definium Therapeutics US, Inc.· Source

• Completed

  Personalized Fiber and Insulin Sensitivity

  NCT05378295· Maastricht University Medical Center· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors

  2023-503905-12-00· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Roflumilast to Treat Cognitive Sequela After Stroke

  NCT04854811· Phase 2· Maastricht University· Source

• Completed

  A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

  NCT04489771· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source

• Completed

  Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20)

  NCT03656718· Phase 1/2· Bristol Myers Squibb International Corporation· Source

• Completed

  A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

  NCT03723655· Phase 2/3· Bristol-Myers Squibb· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure145 works · 2 trials
• Obesity121 works · 11 trials
• Atrial fibrillation108 works · 1 trial
• Alzheimer disease103 works · 0 trials
• Type 2 diabetes96 works · 6 trials
• HIV65 works · 0 trials
• Parkinson disease62 works · 2 trials
• Chronic kidney disease49 works · 0 trials
• Schizophrenia43 works · 1 trial
• Epilepsy42 works · 1 trial
• Multiple sclerosis36 works · 0 trials
• Osteoarthritis36 works · 0 trials
• Mild cognitive impairment36 works · 0 trials
• Depression29 works · 2 trials
• Type 1 diabetes25 works · 0 trials
• Dilated cardiomyopathy24 works · 0 trials
• COPD24 works · 0 trials
• Ankylosing spondylitis22 works · 0 trials
• Fatty liver disease (MASLD/MASH)22 works · 0 trials
• Huntington's disease17 works · 2 trials
• Spinal cord injury16 works · 0 trials
• Ventricular tachycardia15 works · 0 trials
• Head and neck cancer11 works · 0 trials
• Aortic aneurysm11 works · 0 trials
• Irritable bowel syndrome11 works · 0 trials
• Haemophilia9 works · 0 trials
• Duchenne muscular dystrophy8 works · 0 trials
• Keratoconus7 works · 0 trials
• Frontotemporal dementia7 works · 0 trials
• Lewy body dementia7 works · 0 trials